倍他斯汀治疗过敏性结膜炎相关眼部瘙痒的批判性评价
Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis.
作者信息
Wingard Jeremy B, Mah Francis S
机构信息
UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
出版信息
Clin Ophthalmol. 2011;5:201-7. doi: 10.2147/OPTH.S8665. Epub 2011 Feb 15.
Abstract
Bepotastine besilate 1.5% solution is an H(1)-antihistamine recently approved by the Food and Drug Administration for the topical treatment of ocular itching associated with allergic conjunctivitis. Several clinical studies have demonstrated its safety as well as its efficacy versus placebo. This review finds that bepotastine besilate 1.5% solution is a suitable alternative to other agents within the class of H(1)-antihistamines, but there are no clinical trial data to suggest that it holds any specific advantages over other agents.
摘要
1.5%苄普地尔溶液是一种H(1)抗组胺药，最近获美国食品药品监督管理局批准用于局部治疗与过敏性结膜炎相关的眼部瘙痒。多项临床研究已证明其安全性以及与安慰剂相比的疗效。本综述发现，1.5%苄普地尔溶液是H(1)抗组胺药类别中其他药物的合适替代品，但尚无临床试验数据表明它比其他药物具有任何特定优势。
相似文献
1
Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis.
Clin Ophthalmol. 2011;5:201-7. doi: 10.2147/OPTH.S8665. Epub 2011 Feb 15.
2
Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
J Ocul Pharmacol Ther. 2011 Aug;27(4):385-93. doi: 10.1089/jop.2011.0005. Epub 2011 Jun 7.
3
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Clin Ther. 2009 Sep;31(9):1908-21. doi: 10.1016/j.clinthera.2009.09.001.
4
Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference.
Clin Ophthalmol. 2012;6:1731-8. doi: 10.2147/OPTH.S35431. Epub 2012 Oct 29.
5
Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Am J Ophthalmol. 2010 Jul;150(1):122-127.e5. doi: 10.1016/j.ajo.2010.02.007. Epub 2010 May 20.
6
Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
Allergy Asthma Proc. 2012 May-Jun;33(3):265-74. doi: 10.2500/aap.2012.33.3570.
7
Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
Indian J Ophthalmol. 2021 Feb;69(2):257-261. doi: 10.4103/ijo.IJO_2083_20.
8
Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.
Allergy Asthma Proc. 2013 May-Jun;34(3):247-54. doi: 10.2500/aap.2013.34.3671.
9
Bepotastine besilate for the treatment of pruritus.
Expert Opin Pharmacother. 2013 Dec;14(18):2553-69. doi: 10.1517/14656566.2013.849242. Epub 2013 Nov 5.
10
Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis.
J Asthma Allergy. 2018 Mar 23;11:29-39. doi: 10.2147/JAA.S160687. eCollection 2018.
引用本文的文献
1
Ophthalmology in Persian medicine.
J Med Ethics Hist Med. 2014 Dec 3;7:19. eCollection 2014.
本文引用的文献
1
Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Am J Ophthalmol. 2010 Jul;150(1):122-127.e5. doi: 10.1016/j.ajo.2010.02.007. Epub 2010 May 20.
2
Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Exp Eye Res. 2010 Jul;91(1):85-91. doi: 10.1016/j.exer.2010.04.006. Epub 2010 Apr 20.
3
Bepotastine (bepreve)--an ophthalmic H1-antihistamine.
Med Lett Drugs Ther. 2010 Feb 8;52(1331):11-2.
4
New drugs: asenapine, iloperidone, and bepotastine besilate.
J Am Pharm Assoc (2003). 2010 Jan-Feb;50(1):107-10. doi: 10.1331/JAPhA.2010.10505.
5
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Clin Ther. 2009 Sep;31(9):1908-21. doi: 10.1016/j.clinthera.2009.09.001.
6
Multiple H1-antihistamine-induced urticaria.
J Dermatol. 2009 Apr;36(4):224-7. doi: 10.1111/j.1346-8138.2009.00627.x.
7
Downmodulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytes.
Skin Pharmacol Physiol. 2009;22(1):45-8. doi: 10.1159/000183924. Epub 2008 Dec 17.
8
Evaluation of efficacy and sedative profiles of H(1) antihistamines by large-scale surveillance using the visual analogue scale (VAS).
Allergol Int. 2008 Sep;57(3):257-63. doi: 10.2332/allergolint.O-07-525. Epub 2008 Jul 1.
9
Ocular allergy treatment.
Immunol Allergy Clin North Am. 2008 Feb;28(1):189-224, vii. doi: 10.1016/j.iac.2007.12.001.
10
Allergic conjunctivitis.
Immunol Allergy Clin North Am. 2008 Feb;28(1):43-58, vi. doi: 10.1016/j.iac.2007.12.005.
Zotero 插件